Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Classical hematology 1

Conditions

Neoplasms 5Anemia 5Prostatic Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia 1Fatigue 1Critical Illness 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Docetaxel 56Prednisone 36enzalutamide 25Leuprolide 24Magnetic Resonance Spectroscopy 19Abiraterone Acetate 19bicalutamide 17Radiotherapy 15Goserelin 15abiraterone 12acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11olaparib 9Androgen Antagonists 9gallium 68 PSMA-11 8cabazitaxel 8Radiotherapy, Intensity-Modulated 8Metformin 8Ketoconazole 8Gonadotropin-Releasing Hormone 8Cyclophosphamide 8apalutamide 7Doxorubicin 7luprolide acetate gel depot 6cabozantinib 6Radiosurgery 6Estramustine 6Dexamethasone 6Calcitriol 6Biopsy 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms × Darbepoetin alfa × Clear all
NCT00381836 2015-12-04

Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer

University of Aarhus

Phase 2/3 Terminated
140 enrolled
Classical hematologyGenitourinary

Anemia, Fatigue, Neoplasms, Prostatic Neoplasms, Critical Illness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡